ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharmaceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.
Aim of the long-term research cooperation is a new-product development on the basis of ARTES' virus like particle (VLP) and the well-established Hansenula polymorpha expression system fitting to Crucell's vaccine portfolio. The Hansenula system is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. In combination, the unique yeast based VLP approach builds a new and very economical approach to low-cost mass production of safe and effective vaccines.
Under the terms of the long-term research collaboration ARTES is responsible for delivery of the production cell lines and processes to Crucell.
Aim of the long-term research cooperation is a new-product development on the basis of ARTES' virus like particle (VLP) and the well-established Hansenula polymorpha expression system fitting to Crucell's vaccine portfolio. The Hansenula system is the preferred technology for affordable mass vaccination and is recommended by the WHO for hepatitis B vaccination campaigns. In combination, the unique yeast based VLP approach builds a new and very economical approach to low-cost mass production of safe and effective vaccines.
Under the terms of the long-term research collaboration ARTES is responsible for delivery of the production cell lines and processes to Crucell.
